ICR 12000- High-throughput Drug Screening Technology
The ICR 12000 is designed for ultra-high throughput ion channel screening of compound libraries, incorporating multi-channel sampling and enhanced automation features. Based upon the versatility, precision, and sensitivity of Aurora Biomed’s atomic absorption spectroscopy (AAS) instruments, the ICR 12000 is suitable for both ligand-gated and voltage-gated ion channels using cell-based flux assays. With the robustness of Aurora Biomed’s ICR technology, the reader offers high sensitivity for both electrogenic and electroneutral channels and transporters. The incredible 60,000 sample per day throughput of the ICR 12000 enables ion channel researchers to access compound QT liability early in the drug discovery process.
ICR 12000 Ion Channel Reader
- Medium Throughput: Up to 60,000 wells/day
- 12 Channel: Measures 12 sample at a time
- Minimum sample volume: 20 µl
- Accommodation: 96/384-well microplates
- Footprint: H.120 cm X W.95 cm X D.37 cm
- Fuel Source: Acetylene / Compressed Air
- Options: Plate Stacker / Barcode Reader
- Sensitivity: 0.05 ppm detection limit
- Precision: < 5% CV
Features & Benefits
- Programmable and automated solution for up to 60,000 wells/day
- Automatic dilution, calibration and cleaning
- Integrated plate stacker & bar code reader
- Sample dilution not required
- High sensitivity
- On-line dilution
- Eliminates quenching effects associated with fluorescence
- Removes need to work with hazardous radioisotopes
- Avoids work restrictions posed by Rb’s short half-life
- Ideal for hERG channel assays
- Can assess both electrogenic and electroneutral transporters
Researchers from Roche performed high-throughput screening campaigns for modulators of a cation-chloride co-transporter using the ICR 12000.
Download their poster from the 2016 Ion Channel Summit to see how Roche developed a high throughput rubidium (Rb+) uptake assay for measuring NKCC1 function and subsequently screened 1.2 million compounds using Aurora’s ICR 12000.
Development of a non-radioactive Rubidium flux assay to carry out high-throughput screening for electroneutral NKCC1 ion transporter.
Download the publication of the collaboration study with Roche to develop a high throughput rubidium (Rb+) flux assay for measuring electroneutral NKCC1 activity.
Frequently Asked Questions
The non-radioactive flux assay is considered a high throughput solution to investigate a broad range of membrane proteins including electro-neutral targets, to which conventional electrophysiology cannot be applied. The flux assay is capable of establishing the same drug potency rank orders as patch clamps.
Membrane protein targets including voltage-gated and ligand-gated ion channels, co-transporters and pumps.
Cells expressing the ion channels of interest go through a protocol of tracer loading, drug incubation, wash, treatment, and lysis before they are be fed into the ICR. The ICR can fully automate the sample analysis procedure.
The minimal sample loading volume is for 50ul for the ICR 8000 and 20ul for the ICR 12000. The ICR 12000 has a throughput of processing 60000 wells/day as compared to 5000 wells/day on the ICR 8000. The ICR 12000 also has an optional plate stacker.
Standard 96 and 384 well plates.
Our customers include Amgen, Merck, AstraZeneca, Roche, Pfizer, University of British Columbia, Heibei Medical University, and more.